Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mauri

Showing results (211-220 of 371) with videos related to

Pageof 38
Sort By:
Journal for Immunotherapy of Cancer|October 1, 2021
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapyDavid J Pinato, Sam M Murray, Alejandro Forner, et al.
Acta Neurologica Scandinavica|December 10, 2016
EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failureV Villanueva, P Bermejo, J Montoya, et al.
JHEP Reports : Innovation in Hepatology|June 5, 2023
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinomaDavid J Pinato, Takahiro Kaneko, Antonio D'Alessio, et al.
Epilepsy Research|December 27, 2016
Erratum to "Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study" [Epilepsy Res. 126 (2016) 201-210]V Villanueva, M Garcés, F J López-González, et al.
Epilepsy Research|August 14, 2016
Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA studyV Villanueva, M Garcés, F J López-González, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.
Nature|November 26, 2009
Extreme particle acceleration in the microquasar Cygnus X-3M Tavani, A Bulgarelli, G Piano, et al.
The European Physical Journal. C, Particles and Fields|December 29, 2015
Search for long-lived heavy charged particles using a ring imaging Cherenkov technique at LHCbR Aaij, B Adeva, M Adinolfi, et al.
Physical Review Letters|September 26, 2015
Measurement of the ratio of branching fractions B(B[over ¯]^{0}→D^{*+}τ^{-}ν[over ¯]_{τ})/B(B[over ¯]^{0}→D^{*+}μ^{-}ν[over ¯]_{μ})R Aaij, B Adeva, M Adinolfi, et al.
Pageof 38

Showing results (211-220 of 371) with videos related to

Sort By:
Pageof 38
Journal for Immunotherapy of Cancer|October 1, 2021
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapyDavid J Pinato, Sam M Murray, Alejandro Forner, et al.
Acta Neurologica Scandinavica|December 10, 2016
EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failureV Villanueva, P Bermejo, J Montoya, et al.
JHEP Reports : Innovation in Hepatology|June 5, 2023
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinomaDavid J Pinato, Takahiro Kaneko, Antonio D'Alessio, et al.
Epilepsy Research|December 27, 2016
Erratum to "Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study" [Epilepsy Res. 126 (2016) 201-210]V Villanueva, M Garcés, F J López-González, et al.
Epilepsy Research|August 14, 2016
Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA studyV Villanueva, M Garcés, F J López-González, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.
Nature|November 26, 2009
Extreme particle acceleration in the microquasar Cygnus X-3M Tavani, A Bulgarelli, G Piano, et al.
The European Physical Journal. C, Particles and Fields|December 29, 2015
Search for long-lived heavy charged particles using a ring imaging Cherenkov technique at LHCbR Aaij, B Adeva, M Adinolfi, et al.
Physical Review Letters|September 26, 2015
Measurement of the ratio of branching fractions B(B[over ¯]^{0}→D^{*+}τ^{-}ν[over ¯]_{τ})/B(B[over ¯]^{0}→D^{*+}μ^{-}ν[over ¯]_{μ})R Aaij, B Adeva, M Adinolfi, et al.
Pageof 38